Approval · Notice of Compliance 1129 · 2000
ZENAPAX: Notice of Compliance 1129
Issued January 4, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1129
- Date
- January 4, 2000
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Immunosuppressive agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZENAPAX | 02241473 | Cancelled Post Market |
Medicinal ingredients
- DACLIZUMAB 5 MG per ML